CL2021000178A1 - Compuestos de piridin-2-ona útiles como antagonistas de smarca2 - Google Patents

Compuestos de piridin-2-ona útiles como antagonistas de smarca2

Info

Publication number
CL2021000178A1
CL2021000178A1 CL2021000178A CL2021000178A CL2021000178A1 CL 2021000178 A1 CL2021000178 A1 CL 2021000178A1 CL 2021000178 A CL2021000178 A CL 2021000178A CL 2021000178 A CL2021000178 A CL 2021000178A CL 2021000178 A1 CL2021000178 A1 CL 2021000178A1
Authority
CL
Chile
Prior art keywords
treatment
smarca2
methods
pyridin
compounds
Prior art date
Application number
CL2021000178A
Other languages
English (en)
Inventor
Oscar Moradei
John W Lampe
Darren Martin Harvey
John Emmerson Campbell
Kenneth William Duncan
Michael John Munchhof
Original Assignee
Epizyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67539641&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2021000178(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Epizyme Inc filed Critical Epizyme Inc
Publication of CL2021000178A1 publication Critical patent/CL2021000178A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Esta invención se refiere generalmente a compuestos de piridin-2-ona y a métodos para usarlos en el tratamiento de un trastorno, tal como el cáncer o un trastorno asociado a SMARCA2, incluyendo como antagonistas (por ejemplo, inhibidores) de SMARCA2. La presente invención proporciona modalidades de tratamiento, por ejemplo, estrategias, métodos de tratamiento, métodos de estratificación de pacientes, compuestos, combinaciones y composiciones que<br /> son útiles para el tratamiento de trastornos, por ejemplo, trastornos proliferativos, tales como ciertos cánceres. Algunos aspectos de esta invención proporcionan modalidades de tratamiento, métodos, estrategias, compuestos, composiciones, combinaciones y formas de dosificación para el tratamiento de trastornos proliferativos celulares, por ejemplo, cánceres con actividad o función<br /> disminuida, o pérdida de función, de SMARCA4 con un antagonista de SMARCA2.
CL2021000178A 2018-07-24 2021-01-22 Compuestos de piridin-2-ona útiles como antagonistas de smarca2 CL2021000178A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862702481P 2018-07-24 2018-07-24
US201962815208P 2019-03-07 2019-03-07

Publications (1)

Publication Number Publication Date
CL2021000178A1 true CL2021000178A1 (es) 2021-07-09

Family

ID=67539641

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021000178A CL2021000178A1 (es) 2018-07-24 2021-01-22 Compuestos de piridin-2-ona útiles como antagonistas de smarca2

Country Status (16)

Country Link
US (1) US20220356174A1 (es)
EP (1) EP3826999A1 (es)
JP (1) JP2021532181A (es)
KR (1) KR20210038911A (es)
CN (1) CN112739690A (es)
AU (1) AU2019309373A1 (es)
BR (1) BR112021001263A2 (es)
CA (1) CA3106671A1 (es)
CL (1) CL2021000178A1 (es)
CO (1) CO2021002024A2 (es)
IL (1) IL280182A (es)
MA (1) MA53377A (es)
MX (1) MX2021000881A (es)
PH (1) PH12021550119A1 (es)
SG (1) SG11202100158WA (es)
WO (1) WO2020023657A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10118890B2 (en) 2014-10-10 2018-11-06 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
JP2019533022A (ja) 2016-10-24 2019-11-14 ユマニティ セラピューティクス，インコーポレーテッド 化合物及びその使用
EP3566055B1 (en) 2017-01-06 2025-03-12 Janssen Pharmaceutica NV Scd inhibitor for the treatment of neurological disorders
CN110366418A (zh) * 2017-02-28 2019-10-22 埃皮兹姆公司 抑制smarca2用于治疗癌症
CA3083000A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Compounds and uses thereof
WO2019183587A1 (en) 2018-03-23 2019-09-26 Yumanity Therapeutics, Inc. Compounds and uses thereof
KR102551319B1 (ko) 2018-05-14 2023-07-05 길리애드 사이언시즈, 인코포레이티드 Mcl-1 억제제
WO2020154571A1 (en) 2019-01-24 2020-07-30 Yumanity Therapeutics, Inc. Compounds and uses thereof
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
AU2020391106B2 (en) 2019-11-26 2024-03-21 Gilead Sciences, Inc. Processes and intermediates for preparing MCL1 inhibitors
AU2021293943A1 (en) * 2020-06-18 2023-02-23 Epizyme, Inc. SMARCA4 inhibition for the treatment of cancer
WO2022108984A1 (en) 2020-11-19 2022-05-27 Gilead Sciences, Inc. Processes and intermediates for preparing macrocyclic mcl1 inhibitors
EP4714456A2 (en) * 2020-12-16 2026-03-25 Shenzhen Keye Life Technologies, Co., Ltd. Polycyclic compounds for inhibiting rna helicase dhx33 and use thereof
WO2022224924A1 (ja) * 2021-04-23 2022-10-27 日本曹達株式会社 含窒素ヘテロアリール化合物並びに農園芸用殺菌剤、殺線虫剤、および医療用・動物用抗真菌剤
CN114057630B (zh) * 2021-12-23 2023-06-02 郑州大学 吡非尼酮衍生物及其合成方法和应用
EP4556472A1 (en) * 2022-07-14 2025-05-21 Guangzhou Joyo Pharmatech Co., Ltd Use of pyridone derivative
WO2024213125A1 (zh) * 2023-04-14 2024-10-17 南京再明医药有限公司 Brm选择性降解剂及其应用
CN117486856B (zh) * 2023-11-02 2026-02-06 上海毕得医药科技股份有限公司 一种4-溴-5-(三氟甲基)噻吩-2-羧酸甲酯的合成方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JP2011504926A (ja) * 2007-11-28 2011-02-17 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド Ｅｇｆｒキナーゼ阻害剤とｃ−ｋｉｔ阻害剤による併用治療
DK2294065T3 (da) * 2008-01-22 2014-04-28 Vernalis R&D Ltd Indolyl-pyridonderivater med checkpoint kinase 1 inhibitorisk aktivitet
JP5670325B2 (ja) * 2008-06-19 2015-02-18 エックスカバリー ホールディング カンパニー エルエルシー キナーゼ阻害化合物としての置換されたピリダジンカルボキサミド化合物
GB0912499D0 (en) * 2009-07-18 2009-08-26 Vernalis R&D Ltd Indopyl-pyridone derivatives
CN107108613B (zh) * 2014-11-10 2020-02-25 基因泰克公司 布罗莫结构域抑制剂及其用途

Also Published As

Publication number Publication date
AU2019309373A1 (en) 2021-02-11
US20220356174A1 (en) 2022-11-10
WO2020023657A1 (en) 2020-01-30
EP3826999A1 (en) 2021-06-02
CA3106671A1 (en) 2020-01-30
BR112021001263A2 (pt) 2021-04-27
SG11202100158WA (en) 2021-02-25
CN112739690A (zh) 2021-04-30
JP2021532181A (ja) 2021-11-25
CO2021002024A2 (es) 2021-05-20
PH12021550119A1 (en) 2021-10-04
IL280182A (en) 2021-03-01
MX2021000881A (es) 2021-06-08
KR20210038911A (ko) 2021-04-08
MA53377A (fr) 2021-06-02

Similar Documents

Publication Publication Date Title
CL2021000178A1 (es) Compuestos de piridin-2-ona útiles como antagonistas de smarca2
MX2019010149A (es) Inhibicion del smarca2 para el tratamiento del cancer.
MX2020012261A (es) Inhibidores de kras g12c que comprenden un anillo de piperazina y uso de estos en el tratamiento del cancer.
BR112018070361A2 (pt) redução da carga tumoral através da administração de antagonistas do ccr1 em combinação com inibidores de pd-1 ou inibidores de pd-l1
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
PH12021500004A1 (en) Pd-1/pd-l1 inhibitors
MX2016017288A (es) Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer.
MX2017005553A (es) Terapia de combinacion para cancer.
ECSP15042895A (es) Compuestos de biaril-amida como inhibidores de cinasa
MX389700B (es) Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer.
PE20191303A1 (es) Compuestos con actividad antitumoral contra celulas cancerosas que tienen mutaciones en el exon 20 de egfr o her2
MX393818B (es) Terapias de combinación para el tratamiento de cáncer.
NZ725459A (en) Combination therapy for treating cancer with a recombinant poxvirus expressing a tumor antigen and an immune checkpoint molecule antagonist or agonist
ECSP17016797A (es) Indazoles sustituidos con benzilo como inhibidores de bub1
CL2017003456A1 (es) Metodos para tratar tumores de celulas epitelioides
MX2016006177A (es) Método para diseñar células t resistentes a fármacos de quimioterapia para inmunoterapia.
MX2017001031A (es) Móleculas de unión a her2 y cd3 biespecíficas.
MX381582B (es) Terapia de combinacion para el tratamiento de neoplasias malignas.
MX2016010080A (es) Combinacion de un antagonista de muerte programada-1 y un inhibidor de indolamina 2,3-dioxigenasa 1 para el tratamiento del cancer.
NI201500123A (es) Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico
JOP20140141B1 (ar) استخدام 3،2- ثنائي هيدروإيميدازول-[2،1-c] كونازولينات مستبدلة لمعالجة الاورام الليمفاوية
CO7160093A2 (es) Anticuerpos anti-egfr y usos de los mismos
MX2016002137A (es) Ciertas entidades quimicas, composiciones y metodos.
MX373150B (es) Combinaciones de un inhibidor del factor de crecimiento de fibroblasto (fgfr) y un inhibidor del receptor del factor de crecimiento 1 similar a insulina (igf1r).
MX2020003126A (es) Derivados de iminopirimidina ciclicos como inhibidores de cinasa.